EA201690406A1 - Селективные ингибиторы grp94 и способы их применения - Google Patents

Селективные ингибиторы grp94 и способы их применения

Info

Publication number
EA201690406A1
EA201690406A1 EA201690406A EA201690406A EA201690406A1 EA 201690406 A1 EA201690406 A1 EA 201690406A1 EA 201690406 A EA201690406 A EA 201690406A EA 201690406 A EA201690406 A EA 201690406A EA 201690406 A1 EA201690406 A1 EA 201690406A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
selective inhibitors
application
grp94 selective
grp94
Prior art date
Application number
EA201690406A
Other languages
English (en)
Inventor
Габриэла Чиозис
Пэнжун Янь
Паллав Патель
Хардик Дж. Патель
Тони Тальдоне
Чэнхуа Ян
Вэйлинь Сунь
Стефан О. Окьяна
Original Assignee
Мемориал Слоун-Кеттеринг Кэнсэ Сентр
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мемориал Слоун-Кеттеринг Кэнсэ Сентр filed Critical Мемориал Слоун-Кеттеринг Кэнсэ Сентр
Publication of EA201690406A1 publication Critical patent/EA201690406A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • G16C20/64—Screening of libraries

Abstract

Изобретение относится к новым селективным ингибиторам Grp94, композициям, содержащим эффективное количество таких соединений, а также способам лечения или предупреждения состояния, такого как рак, включающим введение животному, нуждающемуся в этом, эффективного количества таких соединений.
EA201690406A 2013-08-16 2014-08-15 Селективные ингибиторы grp94 и способы их применения EA201690406A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361866932P 2013-08-16 2013-08-16
PCT/US2014/051332 WO2015023976A2 (en) 2013-08-16 2014-08-15 Selective grp94 inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
EA201690406A1 true EA201690406A1 (ru) 2016-08-31

Family

ID=52468819

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690406A EA201690406A1 (ru) 2013-08-16 2014-08-15 Селективные ингибиторы grp94 и способы их применения

Country Status (17)

Country Link
US (3) US10421758B2 (ru)
EP (1) EP3033338A4 (ru)
JP (2) JP6539275B2 (ru)
KR (1) KR102319582B1 (ru)
CN (1) CN105899503B (ru)
AU (2) AU2014306417C1 (ru)
BR (1) BR112016003201A2 (ru)
CA (1) CA2921571C (ru)
EA (1) EA201690406A1 (ru)
HK (1) HK1226063A1 (ru)
IL (2) IL244251B (ru)
MX (1) MX370664B (ru)
PH (1) PH12016500511A1 (ru)
SG (2) SG10201801281QA (ru)
TW (1) TWI711618B (ru)
WO (1) WO2015023976A2 (ru)
ZA (1) ZA201601794B (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006084030A2 (en) 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
CA2656202C (en) 2006-06-30 2018-01-16 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibition of hsp90
CN102639534A (zh) 2009-10-07 2012-08-15 斯隆-凯特林癌症研究院 用作Hsp90抑制剂的嘌呤衍生物
EA024647B1 (ru) 2011-04-05 2016-10-31 Слоун-Кеттеринг Инститьют Фо Кэнсэ Рисерч ИНГИБИТОРЫ Hsp90
US9346808B2 (en) 2011-04-05 2016-05-24 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
KR102207770B1 (ko) * 2013-08-05 2021-01-26 트위스트 바이오사이언스 코포레이션 드 노보 합성된 유전자 라이브러리
BR112016003201A2 (pt) 2013-08-16 2017-11-21 Memorial Sloan Kettering Cancer Center inibidores de grp94 seletivos e usos dos mesmos
RU2016128528A (ru) 2013-12-23 2018-01-30 Мемориал Слоун-Кеттеринг Кэнсэ Сентр Способы и реактивы для введения радиоактивной метки
WO2016044629A1 (en) 2014-09-17 2016-03-24 Memorial Sloan Kettering Cancer Center Hsp90-targeted inflammation and infection imaging and therapy
MX2018004112A (es) 2015-10-05 2018-06-20 Memorial Sloan Kettering Cancer Center Terapia de combinacion racional para el tratamiento de cancer.
CN108503643B (zh) * 2017-02-28 2020-09-15 泉州易初生物医药科技有限公司 蛋白酶抑制剂的制备方法
EP3595636A4 (en) * 2017-03-16 2021-01-13 Children's Medical Center Corporation GENETICALLY PRODUCED LIPOSOMES AS TARGETED THERAPEUTICS AGAINST CANCER
WO2019136093A1 (en) * 2018-01-02 2019-07-11 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase (lmptp) and uses thereof
US11774451B2 (en) * 2019-11-21 2023-10-03 The Board Of Trustees Of The Leland Stanford Junior University Molecular vibrational spectroscopic markers for detection of cancer
EP4163298A1 (en) * 2020-06-09 2023-04-12 Kookmin University Industry Academy Cooperation Foundation Antibody specifically binding to grp94 or antigen-binding fragment thereof, and uses thereof
KR20230000050A (ko) 2021-06-24 2023-01-02 최현지 페이크 마스크
CN113663078B (zh) * 2021-06-28 2023-05-16 四川大学 Grp94抑制剂在制备治疗EGFR驱动的癌症的药物中的用途
KR20240012846A (ko) 2022-07-21 2024-01-30 성균관대학교산학협력단 신규한 hdac6 선택적 억제제 및 이의 용도
CN115717144A (zh) * 2022-08-25 2023-02-28 南通市肿瘤医院 抑制hsp90b1表达的小干扰rna及其在膀胱癌衰老中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ288182B6 (en) 1993-07-15 2001-05-16 Minnesota Mining & Mfg Imidazo[4,5-c]pyridine-4-amines and pharmaceutical preparations based thereon
AU2002228771B2 (en) * 2000-11-02 2007-10-25 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to HSP90
US20070129334A1 (en) * 2001-10-30 2007-06-07 Conforma Therapeutics Corporation Orally Active Purine-Based Inhibitors of Heat Shock Protein 90
US7241890B2 (en) 2001-10-30 2007-07-10 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
US7553979B2 (en) 2001-11-09 2009-06-30 Conforma Therapeutics Corporation HSP90-inhibiting zearalanol compounds and methods of producing and using same
KR20060070572A (ko) 2003-09-18 2006-06-23 콘포마 세러퓨틱스 코포레이션 Ｈｓｐ90-저해제로서의 신규 헤테로시클릭 화합물
WO2006084030A2 (en) * 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
WO2007075572A2 (en) 2005-12-22 2007-07-05 Conforma Therapeutics Corporation Orally active purine-based inhibitors of heat shock protein 90
US7595401B2 (en) * 2006-05-12 2009-09-29 Myriad Pharmaceuticals, Inc. Therapeutic compounds and their use in cancer
CA2656202C (en) * 2006-06-30 2018-01-16 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibition of hsp90
CA2665387A1 (en) 2006-10-03 2008-04-10 University Of Southern California Grp78 as a predictor of responsiveness to therapeutic agents
CN101679347B (zh) * 2007-03-20 2014-10-22 柯瑞斯公司 作为hsp90抑制剂的稠和的氨基吡啶
NZ586129A (en) 2007-11-14 2012-06-29 Myrexis Inc Therapeutic compounds and their use in treating diseases and disorders
WO2010042500A2 (en) * 2008-10-06 2010-04-15 Emory University Heat shock protein 90 inhibitors, methods of preparing same, and methods for their use
CN102639534A (zh) 2009-10-07 2012-08-15 斯隆-凯特林癌症研究院 用作Hsp90抑制剂的嘌呤衍生物
US9346808B2 (en) 2011-04-05 2016-05-24 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
EA024647B1 (ru) 2011-04-05 2016-10-31 Слоун-Кеттеринг Инститьют Фо Кэнсэ Рисерч ИНГИБИТОРЫ Hsp90
US8685966B2 (en) * 2011-04-08 2014-04-01 University Of Kansas GRP94 inhibitors
AU2012262520A1 (en) 2011-05-27 2014-01-23 Cytocure Llc Methods, compositions, and kits for the treatment of cancer
DK2729806T3 (en) 2011-07-08 2017-05-15 Sloan-Kettering Inst For Cancer Res APPLICATIONS OF MARKED HSP90 INHIBITORS
BR112016003201A2 (pt) 2013-08-16 2017-11-21 Memorial Sloan Kettering Cancer Center inibidores de grp94 seletivos e usos dos mesmos

Also Published As

Publication number Publication date
JP6848009B2 (ja) 2021-03-24
AU2019202669A1 (en) 2019-05-09
IL244251B (en) 2019-07-31
HK1226063A1 (zh) 2017-09-22
AU2019202669B2 (en) 2020-12-03
IL267681B (en) 2022-11-01
CN105899503A (zh) 2016-08-24
AU2014306417A1 (en) 2016-03-17
IL244251A0 (en) 2016-04-21
TW201516047A (zh) 2015-05-01
US10421758B2 (en) 2019-09-24
IL267681A (en) 2019-08-29
US11267816B2 (en) 2022-03-08
US20230123747A1 (en) 2023-04-20
EP3033338A2 (en) 2016-06-22
CN105899503B (zh) 2020-08-18
JP2016533384A (ja) 2016-10-27
KR20160043534A (ko) 2016-04-21
ZA201601794B (en) 2019-09-25
TWI711618B (zh) 2020-12-01
CA2921571C (en) 2022-04-05
SG11201601542SA (en) 2016-04-28
PH12016500511A1 (en) 2016-06-13
WO2015023976A3 (en) 2015-04-23
WO2015023976A2 (en) 2015-02-19
US20160194328A1 (en) 2016-07-07
AU2014306417C1 (en) 2019-07-25
EP3033338A4 (en) 2017-06-14
MX2016002077A (es) 2016-07-21
CA2921571A1 (en) 2015-02-19
MX370664B (es) 2019-12-19
JP2019178147A (ja) 2019-10-17
AU2014306417B2 (en) 2019-01-17
BR112016003201A2 (pt) 2017-11-21
IL267681B2 (en) 2023-03-01
KR102319582B1 (ko) 2021-11-04
US20200102312A1 (en) 2020-04-02
SG10201801281QA (en) 2018-04-27
JP6539275B2 (ja) 2019-07-03

Similar Documents

Publication Publication Date Title
EA201690406A1 (ru) Селективные ингибиторы grp94 и способы их применения
EA201691354A1 (ru) Терапевтические ингибирующие соединения
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201690753A1 (ru) Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
EA201690734A1 (ru) Ингибиторы бромодомена
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201690881A1 (ru) Соединения-ингибиторы аутотаксина
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201591327A1 (ru) Замещенные пирролопиримидиновые соединения, их композиции и способы лечения с использованием таких соединений
EA201791516A1 (ru) Способы комбинированного лечения злокачественных опухолей
EA201591746A1 (ru) Способы и композиции для ингибирования бромодомен-содержащих белков
EA201592068A1 (ru) Ингибиторы энхансера zeste гомолога 2
EA201691155A1 (ru) Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
EA201690764A1 (ru) Ингибитор грелин-o-ацилтрансферазы
EA201790576A1 (ru) Спироциклические ингибиторы катепсина с
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA201690844A1 (ru) Ингибиторы gsk-3
EA201591705A1 (ru) Композиции и способы для диагностики и лечения рака печени
EA201691881A1 (ru) Новые соединения
EA201890331A1 (ru) Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201500851A1 (ru) ЭСТРА-1,3,5(10),16-ТЕТРАЕН-3-КАРБОКСАМИДЫ ДЛЯ ИНГИБИРОВАНИЯ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ (AKR1C3)